Clinical Trial of Immunomodulatory Therapy Using Anti-Thymocyte Globulin and Pegfilgrastim for Recently Onset Type 1 Diabetes - CRITICA

We evaluated the safety and efficacy of immunomodulatory therapy using anti-thymocyte globulin and pegfilgrastim in recently onset type 1 diabetes. In terms of safety, no grade 4 and 5 severe adverse events were observed. In terms of efficacy, although some analyses showed potantial effects for the preservation of endogenous insulin secretion, the results were not significant. In the future, the efficacy of the treatment should be validated in the trial with more ceses.